European Commission approves Nucala treatment in three diseases
This marks the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA)
Read Moreby Lucy Parsons | Nov 17, 2021 | News | 0
This marks the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA)
Read Moreby Lucy Parsons | Sep 22, 2021 | News | 0
Positive opinions recommend approval for mAb in three additional eosinophil-driven diseases
Read Moreby Selina McKee | Feb 3, 2021 | News | 0
Final guidance on the drug’s use to treat patients with severe eosinophilic asthma on the NHS has now been published
Read Moreby Lucy Parsons | Dec 10, 2020 | News | 0
Submission is based on data from the pivotal SYNAPSE study
Read Moreby Selina McKee | Nov 2, 2020 | News | 0
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read Moreby Selina McKee | Apr 6, 2020 | News | 0
Nucala is the first anti-IL5 biologic to report positive Phase III results in patients with the condition says GSK
Read Moreby Anna Smith | Jun 7, 2019 | News | 0
The two new methods, autoinjector and a pre-filled safety syringe, are for patients or caregivers to administer once every four weeks.
Read Moreby Anna Smith | Jan 4, 2019 | News | 0
The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.
Read Moreby Selina McKee | Nov 20, 2018 | News | 0
GlaxoSmithKline is seeking to expand the use of its biologic Nucala in the US to include children aged six to 11 years with severe eosinophilic asthma.
Read Moreby Selina McKee | Nov 2, 2018 | News | 0
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control in patients taking its biologic Nucala.
Read Moreby Selina McKee | Sep 10, 2018 | News | 0
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
Read Moreby Selina McKee | Aug 30, 2018 | News | 0
GlaxoSmithKline’s Nucala has been approved for use in paediatric patients with severe eosinophilic asthma.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
